MATE Act CME

The Drug Enforcement Administration (DEA) now requires that all DEA certificate holders complete continuing education comprising 8 hours of training specific to the management of substance use disorders (SUDs) in order to obtain DEA registration.  Learn More

The IAS–USA is excited to support clinicians in meeting these new requirements with a free, 6-part webinar series comprising 8 hours of training to help you provide the best possible care for your patients! Consistent with the IAS-USA mission, the series will include specific guidance on SUDs in people with HIV, on subjects ranging from the etiology and screening of SUDs to the management of specific SUDs, such as opioid, stimulant, tobacco, and alcohol use disorders. The series, spearheaded by Sandra Springer, MD, and Ellen F. Eaton, MD, will include live webinars, which will each be available on-demand for those who wish to learn at their own pace.

Bonus Q and A Webinar is Now Open for Registration

Substance Use Disorder Webinar Series: Bonus Question-and-Answer Session

Presenters: Ellen F. Eaton, MD, and Sandra A. Springer, MD
February 6, 2024
11:00 AM – 12:00 PM PT

*Please note that CME is not offered for this session

Now Available On-Demand

(Part 1 of 6) Substance Use Disorder (SUD) 101: Why Should We Care About SUD in Patients With HIV?

Presenter: Sandra Springer, MD; Moderator: Ellen F. Eaton, MD
August 22, 2023
10:00 AM – 11:15 AM PT

Learning Objectives

On completion of this activity, learners will be able

• Explain the epidemiology of substance use and its impact on HIV treatment
• Identify the “why” behind mastering the basics of substance use of disorder treatment
• Screen for substance use disorders in HIV prevention and treatment settings

(Part 2 of 6) Substance Use Disorder (SUD) 101: How Should We Care For SUD in Patients With HIV?

Presenter: Ellen F. Eaton, MD; Moderator: Sandra Springer, MD
September 19, 2023
10:00 AM – 11:15 AM PT

Learning Objectives

On completion of this activity, learners will be able:

• Initiate treatment for substance use disorder (SUD) in patients with HIV
• Consider alternative plans to help patients with SUD and HIV stay retained in care
• Educate patients with HIV and SUD on the importance of overdose prevention/harm reduction

(Part 3 of 6) Substance Use Disorder: Initiating Buprenorphine in the Fentanyl Era and Other Treatment Considerations in Patients With Opioid Use Disorder and HIV

Presenter: Leah J. Leisch, MD; Moderator: Sandra A. Springer, MD
October 5, 2023
11:30 AM – 12:45 PM PT

Learning Objectives

On completion of this activity, learners will be able to:

• List the treatment options for opioid use disorder in patients with HIV
• Discuss the 3 FDA-approved medications for opioid use disorder
• Describe standard initiation of buprenorphine in HIV patients with opioid use disorder
• Describe alternate strategies of initiation of buprenorphine in HIV patients with opioid use disorder and significant fentanyl use

(Part 4 of 6) Substance Use Disorder: Alcohol and Tobacco Use Disorders in Patients With HIV

Presenter: Geetanjali Chander, MD, MPH; Moderator: Ellen F. Eaton, MD
November 30, 2023
10:30 AM – 11:45 AM PT

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the roles of unhealthy alcohol use and tobacco smoking on HIV-related morbidity and mortality
• Implement optimal screening methods for alcohol and tobacco use in HIV clinical settings
• List evidence-based therapies for alcohol and tobacco use among people with HIV

(Part 5 of 6) Substance Use Disorder: Stimulant Use Disorder, Harm Reduction, and Contingency Management in Patients With HIV

Presenter: Steven J. Shoptaw, PhD; Moderator: Sandra A. Springer, MD
December 20, 2023
10:00 AM – 11:15 AM PT

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the role of stimulant use disorder on HIV-related morbidity and mortality
• Make clinic changes to implement contingency management and medications as a tool to treat patients with stimulant use disorders
• List evidence-based therapies for harm reduction in patients with stimulant use disorder and HIV

(Part 6 of 6) Substance Use Disorder: Future Directions, Long-Acting Injectables, and Novel Therapies

Presenter: Michelle R. Lofwall, MD; Moderator: Ellen F. Eaton, MD
January 24, 2024
2:00 PM – 3:30 PM PT

Learning Objectives

On completion of this activity, learners will be able to:

• List the rationale (who, when, why) for the use of long-acting injectables buprenorphine (LAI-bup) for opioid use disorder among marginalized patient populations including those with infectious diseases
• Explain the relevant clinical pharmacology, storage, and administration requirements of LAI-bup to support successful implementation of the process of initiating and maintaining patients on LAI-bup for opioid use disorder (ie, extended-release buprenorphine and weekly/monthly injectable buprenorphine)
• Describe innovative care models for special populations utilizing LAI medication, such as pregnant persons and persons with serious infections transitioning from the acute care hospital setting

Also Available for SUD CME Credit

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol
Presented by Sandra Springer, MD. Available for CME credit as part of the IAS–USA Annual Update on HIV Management.

https://www.iasusa.org/courses/on-demand-hiv-update-2023-atlanta/